Furthermore, there is evidence to suggest that the CCR5Δ32 mutation, which leads to reduced CCR5 expression at the cell surface, is associated with a protective effect in patients with RA [14-16]; however, this finding has not been consistent [17,18]. This evidence concerns the gene CCR5 and rheumatoid arthritis.